Bayer fights India’s compulsory licence ruling
German pharmaceutical company Bayer has appealed a decision by India’s Controller of Patents to grant a compulsory license over its cancer treatment drug sorafenib
Unlock this article.
The content you are trying to view is exclusive to our subscribers.
To unlock this article: